In vivo production of psilocybin in E. coli
Metabolic Engineering September 21, 2019 Alexandra M. Adams, Nicholas A. Kaplan, Zhangyue Wei et al. 83 citations
Psilocybin, a psychedelic compound, has shown promise in drug studies for its potential therapeutic effects. In trials involving over 400 participants, 70% reported significant improvements in mood and anxiety after treatment. The biochemistry behind psilocybin involves complex interactions with serotonin receptors, influencing pharmacology and drug metabolism. Escherichia coli is being explored for bioproduction of this alkaloid through chemical synthesis techniques. Advances in recombinant DNA technology may enhance the efficiency of psilocybin production, opening new avenues for mental health treatments and pharmacogenetics.